1. Home
  2. HLNE vs BLCO Comparison

HLNE vs BLCO Comparison

Compare HLNE & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HLNE
  • BLCO
  • Stock Information
  • Founded
  • HLNE 1991
  • BLCO 1853
  • Country
  • HLNE United States
  • BLCO Canada
  • Employees
  • HLNE N/A
  • BLCO N/A
  • Industry
  • HLNE Investment Managers
  • BLCO Ophthalmic Goods
  • Sector
  • HLNE Finance
  • BLCO Health Care
  • Exchange
  • HLNE Nasdaq
  • BLCO Nasdaq
  • Market Cap
  • HLNE 5.3B
  • BLCO 5.2B
  • IPO Year
  • HLNE 2017
  • BLCO 2022
  • Fundamental
  • Price
  • HLNE $134.06
  • BLCO $16.54
  • Analyst Decision
  • HLNE Hold
  • BLCO Hold
  • Analyst Count
  • HLNE 8
  • BLCO 14
  • Target Price
  • HLNE $159.88
  • BLCO $16.46
  • AVG Volume (30 Days)
  • HLNE 489.6K
  • BLCO 484.1K
  • Earning Date
  • HLNE 11-04-2025
  • BLCO 10-29-2025
  • Dividend Yield
  • HLNE 1.61%
  • BLCO N/A
  • EPS Growth
  • HLNE 19.80
  • BLCO N/A
  • EPS
  • HLNE 5.55
  • BLCO N/A
  • Revenue
  • HLNE $733,070,000.00
  • BLCO $4,976,000,000.00
  • Revenue This Year
  • HLNE $4.09
  • BLCO $8.12
  • Revenue Next Year
  • HLNE $19.26
  • BLCO $5.81
  • P/E Ratio
  • HLNE $24.24
  • BLCO N/A
  • Revenue Growth
  • HLNE 13.01
  • BLCO 6.23
  • 52 Week Low
  • HLNE $111.98
  • BLCO $10.45
  • 52 Week High
  • HLNE $203.72
  • BLCO $20.71
  • Technical
  • Relative Strength Index (RSI)
  • HLNE 64.44
  • BLCO 66.53
  • Support Level
  • HLNE $111.98
  • BLCO $14.89
  • Resistance Level
  • HLNE $123.00
  • BLCO $16.75
  • Average True Range (ATR)
  • HLNE 4.25
  • BLCO 0.57
  • MACD
  • HLNE 2.73
  • BLCO 0.11
  • Stochastic Oscillator
  • HLNE 91.42
  • BLCO 91.40

About HLNE Hamilton Lane Incorporated

Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: